Neoadjuvant Atezolizumab and Chemotherapy for Non-Squamous Non-Small Cell Lung Cancer: Efficacy and Safety Results of an Open-Label, Single-Arm, Phase II Trial.
Int J CancerApr 19, 2026 (epub)
Benedikt Niedermaier, Tilmann Bochtler, Florian Eichhorn et al.
✦ AI-curated · Sources linked
In 30 seconds
This open-label, single-arm Phase II trial assessed the efficacy and safety of neoadjuvant atezolizumab combined with carboplatin/nab-paclitaxel in 20 patients with resectable non-squamous non-small cell lung cancer. The study found a major pathologic response (MPR) rate of 45%, with 25% achieving complete pathological response, indicating a promising approach for this patient population.
Key findings
- Major pathologic response (MPR) was observed in 9 patients (45%).
- 5 patients (25%) achieved complete pathological response.
- 65% of patients experienced treatment-related adverse events of grade 3 or higher.
- All patients underwent complete anatomical resection (R0).
Why it matters
The study highlights the potential of combining immunotherapy with chemotherapy as a neoadjuvant treatment for resectable non-small cell lung cancer, which may improve patient outcomes and surgical success rates.